Search

Your search keyword '"Chen, Ke-Neng"' showing total 273 results

Search Constraints

Start Over You searched for: Author "Chen, Ke-Neng" Remove constraint Author: "Chen, Ke-Neng" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
273 results on '"Chen, Ke-Neng"'

Search Results

6. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

7. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

8. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

11. Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China.

12. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study

15. Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

17. The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

19. Technical Notes

21. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

22. A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

24. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

25. Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816

26. Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816

27. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

28. Supplementary Data from Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases

31. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

33. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

37. Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)

38. Expert consensus on perioperative treatment for non-small cell lung cancer

39. Pre-operative oil ingestion reduces the probability of thoracic duct trunk ligation during esophagectomy.

41. Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

42. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

47. Expert consensus on resection of chest wall tumors and chest wall reconstruction

49. IGFBP1 hi WNT3A lo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor.

Catalog

Books, media, physical & digital resources